SCHEMBL6035567

SCHEMBL6035567

O=C(O)Cc1cccc(F)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.55
CXCL8 P10145 2/20 0.54
ALB P02768 1/20 0.52
DUSP3 P51452 1/20 0.51
PTPN5 P54829 1/20 0.51
PTPN11 Q06124 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
TDP1 Q9NUW8 1/20 0.48
PTGS2 P35354 3/20 0.47
ANO1 Q5XXA6 1/20 0.45
HMGB1 P09429 1/20 0.44
ERN1 O75460 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7937087 0.85 AKR1B1 (0.67) AKR1B1CXCL8ALBDUSP3PTPN5
SCHEMBL28357376 0.82 ANO1 (0.47) CXCL8ALBANO1HMGB1ERN1
SCHEMBL723768 0.82 CXCL8 (0.56) AKR1B1CXCL8DUSP3PTPN5PTPN11
SCHEMBL8645 0.81 CXCL8 (0.65) AKR1B1CXCL8TDP1PTGS2KDM4E
SCHEMBL29533621 0.81 CXCL8 (0.65) AKR1B1CXCL8TDP1PTGS2KDM4E
SCHEMBL27996630 0.81 ALB (0.48) ALBHMGB1
SCHEMBL11118766 0.80 CXCL8 (0.77) AKR1B1CXCL8DUSP3PTPN5PTPN11
SCHEMBL7165040 0.80 CXCL8 (0.77) AKR1B1CXCL8ALBPTGS2
SCHEMBL28134586 0.80 CXCL8 (0.54) AKR1B1CXCL8DUSP3PTPN5PTPN11
SCHEMBL28005176 0.79 IAPP (0.47) CXCL8ALBANO1HMGB1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 AKR1B1 101/4885CXCL8 4247/4885ALB 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.